XML 29 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Employee Benefit Plans
3 Months Ended
Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Employee Benefit Plans
Employee Benefit Plans

Equity Incentive Plans

The Company’s equity incentive plans include the 2015 Equity Incentive Plan (the “2015 Plan”), the 2006 Equity Incentive Plan (the “2006 Plan”), the Amended and Restated 1996 Stock Plan (the “1996 Plan”), various equity incentive plans assumed through acquisitions, and the 2008 Employee Stock Purchase Plan (the “ESPP”). Under these plans, the Company has granted (or, in the case of acquired plans, assumed) stock options, restricted stock units (“RSUs”), restricted stock awards (“RSAs”), and performance share awards (“PSAs”).

The 2015 Plan was adopted and approved by the Company's stockholders in May 2015 and had an initial authorized share reserve of 38.0 million shares of common stock plus the addition of any shares subject to outstanding awards under the 2006 Plan and the 1996 Plan that were outstanding as of May 19, 2015, and that subsequently expire or otherwise terminate, up to a maximum of an additional 29.0 million shares. As of March 31, 2016, an aggregate of 22.1 million shares were subject to outstanding equity awards under the 2015 Plan and the 2006 Plan, and no shares were subject to outstanding equity awards under the 1996 Plan. As of March 31, 2016, 23.6 million shares were available for future issuance under the 2015 Plan and no shares were available for future issuance under the 2006 Plan or the 1996 Plan.

The ESPP was adopted and approved by the Company's stockholders in May 2008. To date, the Company's stockholders have approved a share reserve of 26.0 million shares of the Company's common stock for issuance under this plan, which includes an additional 7.0 million shares approved by the Company's stockholders in May 2015. The ESPP permits eligible employees to acquire shares of the Company’s common stock at a 15% discount to the offering price (as determined in the ESPP) through periodic payroll deductions of up to 10% of base compensation, subject to individual purchase limits of 6,000 shares in any twelve-month period or $25,000 worth of stock, determined at the fair market value of the shares at the time the stock purchase option is granted, in one calendar year. As of March 31, 2016, approximately 19.7 million shares have been issued and 6.3 million shares remain available for future issuance under the ESPP.

In connection with certain past acquisitions, the Company assumed stock options, RSUs, and RSAs under the assumed stock plans of the acquired companies and exchanged the assumed awards for the Company's stock options, RSUs, and RSAs, respectively. No new equity awards can be granted under these assumed plans. As of March 31, 2016, stock options, RSUs, and RSAs representing approximately 1.0 million shares of common stock were outstanding under all awards assumed through the Company's acquisitions.

Stock Option Activities

The following table summarizes the Company’s stock option activity and related information as of and for the three months ended March 31, 2016 (in millions, except for per share amounts and years):
 
Outstanding Options
 
Number of Shares
 
Weighted Average
Exercise Price
per Share
 
Weighted Average
Remaining
Contractual Term
(In Years)
 
Aggregate
Intrinsic
Value
Balance as of December 31, 2015
3.6

 
$
27.52

 
 
 
 
Exercised
(0.4
)
 
14.50

 
 
 
 
Balance as of March 31, 2016
3.2

 
$
29.23

 
2.0
 
$
9.2

 
 
 
 
 
 
 
 
As of March 31, 2016:
 
 
 
 
 
 
 
Vested and expected-to-vest options
3.2

 
$
29.27

 
2.0
 
$
9.1

Exercisable options
3.1

 
$
30.18

 
1.8
 
$
6.7



The aggregate intrinsic value represents the difference between the Company’s closing stock price on the last trading day of the period, which was $25.51 per share as of March 31, 2016, and the exercise price of the applicable options multiplied by the number of related options. The pre-tax intrinsic value of options exercised, representing the difference between the fair market value of the Company’s common stock on the date of exercise and the exercise price of each option, was $3.9 million for the three months ended March 31, 2016.

Restricted Stock Unit, Restricted Stock Award, and Performance Share Award Activities

The following table summarizes the Company’s RSU, RSA, and PSA activity and related information as of and for the three months ended March 31, 2016 (in millions, except per share amounts and years):
 
Outstanding RSUs, RSAs, and PSAs
 
Number of Shares
 
Weighted Average
Grant-Date Fair
Value per Share
 
Weighted Average
Remaining
Contractual Term
(In Years)
 
Aggregate
Intrinsic
Value
Balance as of December 31, 2015
18.6

 
$
22.71

 
 
 
 
RSUs granted (1)(3)
6.1

 
24.97

 
 
 
 
PSAs granted (2)(3)
0.7

 
23.70

 
 
 
 
RSUs vested
(3.5
)
 
21.73

 
 
 
 
RSAs vested
(0.6
)
 
21.02

 
 
 
 
PSAs vested
(0.7
)
 
21.61

 
 
 
 
RSUs canceled
(0.3
)
 
22.29

 
 
 
 
PSAs canceled
(0.4
)
 
21.69

 
 
 
 
Balance as of March 31, 2016
19.9

 
$
23.73

 
1.5
 
$
506.9

________________________________
(1) 
Includes service-based and market-based RSUs granted under the 2015 Plan according to its terms.
(2) 
The number of shares subject to PSAs granted represents the aggregate maximum number of shares that may be issued pursuant to the award over its full term. The aggregate number of shares subject to these PSAs that would be issued if performance goals determined by the Compensation Committee are achieved at target is 0.4 million shares. Depending on achievement of such performance goals, the range of shares that could be issued under these awards is 0 to 0.7 million shares.
(3) 
The grant date fair value of RSUs and PSAs were reduced by the present value of dividends expected to be paid on the underlying shares of common stock during the requisite and derived service period as these awards are not entitled to receive dividends until vested. On January 27, 2016, the Company declared a cash dividend of $0.10 per share of common stock, or $38.3 million in the aggregate, to stockholders of record on March 1, 2016, which was paid on March 22, 2016.

Employee Stock Purchase Plan

The ESPP is implemented in a series of offering periods, each currently six months in duration, or such other period as determined by the Board. Employees purchased 1.3 million and 1.4 million shares of common stock through the ESPP at an average exercise price of $20.06 and $19.32 per share for the three months ended March 31, 2016 and March 31, 2015, respectively.

Valuation Assumptions

The weighted-average assumptions used and the resulting estimates of fair value for ESPP and market-based RSUs during the three months ended March 31, 2016 and March 31, 2015 were as follows:
 
Three Months Ended March 31,
 
2016
 
2015
ESPP (1):
 
 
 
Volatility
35%
 
30%
Risk-free interest rate
0.5%
 
0.1%
Expected life (years)
0.5
 
0.5
Dividend yield
1.7%
 
1.9%
Weighted-average fair value per share
$5.95
 
$5.23
 
 
 
 
Market-based RSUs (2):
 
 
 
Volatility
36%
 
34%
Risk-free interest rate
1.2%
 
1.4%
Dividend yield
1.7%
 
1.8%
Weighted-average fair value per share
$14.71
 
$14.97
________________________________
(1) 
The Black-Scholes-Merton option-pricing model is utilized to estimate the fair value of shares issuable under the ESPP.
(2) 
The fair value of market-based RSUs utilizes a Monte Carlo valuation methodology. The Company amortizes the fair value of these awards over the derived service period adjusted for estimated forfeitures for each separately vesting tranche of the award. Provided that the derived service is rendered, the total fair value of the market-based RSUs at the date of grant is recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.     

Share-Based Compensation Expense

Share-based compensation expense associated with stock options, RSUs, RSAs, PSAs, and ESPP was recorded in the following cost and expense categories in the Condensed Consolidated Statements of Operations (in millions):
 
Three Months Ended March 31,
 
2016
 
2015
Cost of revenues - Product
$
1.9

 
$
1.7

Cost of revenues - Service
3.5

 
3.4

Research and development
32.3

 
30.7

Sales and marketing
9.4

 
5.8

General and administrative
4.7

 
4.4

Total
$
51.8

 
$
46.0



The following table summarizes share-based compensation expense by award type (in millions):
 
Three Months Ended March 31,
 
2016
 
2015
Stock options
$
1.2

 
$
2.2

RSUs, RSAs, and PSAs
46.8

 
40.6

ESPP
3.8

 
3.2

Total
$
51.8

 
$
46.0



The following table presents unrecognized compensation cost, adjusted for estimated forfeitures, recognized over a weighted-average period related to unvested stock options, RSUs, RSAs, and PSAs as of March 31, 2016 (in millions, except years):
 
Unrecognized
Compensation Cost
 
Weighted Average
Period
(In Years)
Stock options
$
0.9

 
0.4
RSUs, RSAs, and PSAs
$
279.4

 
2.1